Phase Ib, open-label, multicenter dose-escalation study followed by an extension phase to evaluate the safety pharmacokinetics and activity of RO5479599 a glycoengineered antibody against HER3, administered incombination with pertuzumab and paclitaxel in

Cancer type: Breast cancer

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, breast cancer, HER2, HER3

Status: Completed

Link to